Abstract 805P
Background
Complete tumor resection is the most relevant prognostic factor for overall survival in high grade serous ovarian cancer (HGSOC) patients. The current standard for classification of postoperative residual disease (RD) is surgeon´s subjective evaluation at the end of surgery. Thus, a reliable objective predictive marker is currently missing.
Methods
In this prospective single-center feasibility study, patients with HGSOC, who underwent surgery between July 2021 to December 2022, were included. Tumor tissue was assessed intraoperatively and blood samples were performed preoperatively, at day 2 and 10 postoperatively and subsequently at cycle 1, 3 and 6 of chemotherapy. Low-coverage whole genome sequencing (WGS) was used to identify structural variants (SV), single nucleotide variants (SNVs) and indels in tumor tissue in order to develop personalized digital PCR (dPCR) fingerprint assays.
Results
So far, 33 patients are included in the present analysis, with a median follow up time of 7 (IQR 2-10) months. In all tumor samples, dPCR assays were successfully developed and validated, with a median of 5 biomarkers (SVs and SNVs) per patient. For each patient, an individual SV profile could be established, which remained largely constant throughout multiple tumor localizations of each patient. 32/33 (97%) patients had circulating tumor DNA (ctDNA) detected at baseline at levels ranging from 0.0005 - 31% VAF. Three (10%) patients have been lost to follow without postoperative ctDNA samples. ctDNA was persistently detected in all patients with macroscopic tumor residuals. A significant decrease in ctDNA was observed in all patients with stage I-IIIB disease who had macroscopic complete resection (8 patients). In 8/22 (36%) patients with complete resection, ctDNA decreased below the detection limit. Clinical follow up is ongoing, and analysis of longitudinal samples will be presented at the congress.
Conclusions
In this feasibility study, tumor-informed ctDNA was preoperatively detectable in 97% participants. In patients with multiple tumor biopsies, the fingerprint could be used for monitoring of each location. A decrease in ctDNA detection correlated with complete tumor resection.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Medical University of Vienna.
Funding
SAGA Diagnostics.
Disclosure
C. Grimm: Financial Interests, Personal, Advisory Board: AstraZeneca, Celgene, Clovis, Eisai, GSK, MSD, PharmaMar, Roche, Sandoz; Financial Interests, Personal, Invited Speaker: Amgen, AstraZeneca, Eisai, GSK, MSD, PharmaMar, Roche; Financial Interests, Institutional, Research Grant: AstraZeneca, Meda Pharma, Roche Diagnostics. L. Saal: Financial Interests, Personal and Institutional, Ownership Interest: SAGA Diagnostics. C. Brueffer: Financial Interests, Personal and Institutional, Stocks/Shares: SAGA Diagnostics. N. Segui Gracia: Financial Interests, Personal and Institutional, Full or part-time Employment: SAGA Diagnostics. M. Alcaide: Financial Interests, Personal and Institutional, Stocks/Shares: SAGA Diagnostics. S. Polterauer: Financial Interests, Personal, Advisory Board: AstraZeneca, GSK, MSD. L. Oton: Financial Interests, Personal and Institutional, Stocks/Shares: SAGA Diagnostics. Y. Chen: Financial Interests, Personal and Institutional, Full or part-time Employment: SAGA Diagnostics. All other authors have declared no conflicts of interest.
Resources from the same session
648P - Medium to long-term effects of the COVID-19 pandemic on colorectal cancer diagnosis and management in Italy: Preliminary findings from an updated analysis of the real-world multicenter COVID-DELAY study
Presenter: Alessandro Parisi
Session: Poster session 11
649P - The genomic landscape of appendiceal adenocarcinoma (AA) revealed by 855 whole exome sequences (WES)
Presenter: Michael White
Session: Poster session 11
650P - Genomic profiling of small bowel adenocarcinoma: A pooled analysis
Presenter: Thomas Aparicio
Session: Poster session 11
651P - DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: A multicenter propensity score matching study
Presenter: Christophe Borg
Session: Poster session 11
726P - Circulating cell-free DNA-based biomarkers as a new tool for prognosis and surveillance of adrenocortical carcinoma
Presenter: Cristina Ronchi
Session: Poster session 11
727P - Clinical outcome of anlotinib (A) and tislelizumab (T) in metastatic adrenocortical carcinoma(mACC): A one-arm single-center experience
Presenter: HAO LI
Session: Poster session 11
728P - Brain metastases in advanced thyroid carcinoma: Clinical and molecular characteristics and outcomes
Presenter: Thais Megid
Session: Poster session 11
729P - Prognostic significance of nodal micrometastases in patients with non-functioning pancreatic neuroendocrine tumors (NF-PanNETs): A survival analysis from a prospective observational study
Presenter: Valentina Andreasi
Session: Poster session 11
730P - The outcome of combine radioligand and CAPTEM therapy in patients with advanced, unresectable, progressive GEP-NET
Presenter: Jaroslaw Cwikla
Session: Poster session 11